fool.com · 24 jul

These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead

Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area. Exelixis has carved out a niche in the cancer-drug market, which much larger companies typically dominate.

zacks.com · 24 jul

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?

businesswire.com · 22 jul

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event will be available via the Internet from the company's website. To access the conference call, please dial (800) 715-9871 (domes.

defenseworld.net · 22 jul

Bank of New York Mellon Corp Sells 57,995 Shares of Exelixis, Inc. $EXEL

Bank of New York Mellon Corp lowered its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 2.8% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,986,035 shares of the biotechnology company's stock after selling 57,995 shares during the

zacks.com · 20 jul

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

defenseworld.net · 18 jul

Allspring Global Investments Holdings LLC Acquires 323,895 Shares of Exelixis, Inc. $EXEL

Allspring Global Investments Holdings LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 23.4% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,707,715 shares of the biotechnology company's stock after acquiring an additional 323,895 shares during the period. Allspring Global

zacks.com · 16 jul

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

fool.com · 10 jul

3 Under-the-Radar Stocks to Buy and Hold

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.